MIT researchers have developed a simple, low-cost technology to administer powerful drug formulations that are too viscous to be injected using conventional medical syringes.Get more news about Advanced Syringe Auto Feeder,you can vist our website!

The technology, which is described in a paper published today in the journal Advanced Healthcare Materials, makes it possible to inject high-concentration drugs and other therapies subcutaneously. It was developed as a solution for highly effective, and extremely concentrated, biopharmaceuticals, or biologics, which typically are diluted and injected intravenously.

"Where drug delivery and biologics are going, injectability is becoming a big bottleneck, preventing formulations that could treat diseases more easily," says Kripa Varanasi, MIT professor of mechanical engineering. "Drug makers need to focus on what they do best, and formulate drugs, not be stuck by this problem of injectability."

Leaders at the Bill and Melinda Gates Foundation brought the injectability problem to Varanasi after reading about his previous work on dispensing liquids, which has attracted the attention of industries ranging from aviation to makers of toothpaste. A main concern of the foundation, Varanasi says, was with providing high-concentration vaccines and biologic therapies to people in developing countries who could not travel from remote areas to a medical setting.

In the current pandemic, Varanasi adds, being able to stay home and subcutaneously self-administer medication to treat diseases such as cancer or auto-immune disorders is also important in developed countries such as the United States.Varanasi and Vishnu Jayaprakash, a graduate student in MIT's mechanical engineering department who is the first author on the paper, designed a system that would make subcutaneous injection of high-concentration drug formulations possible by reducing the required injection force, which exceeded what is possible with manual subcutaneous injection with a conventional syringe.

In their system, the viscous fluid to be injected is surrounded with a lubricating fluid, easing the fluid's flow through the needle. With the lubricant, just one-seventh of the injection force was needed for the highest viscosity tested, effectively allowing subcutaneous injection of any of the more than 100 drugs otherwise considered too viscous to be administered in that way.

"We can enable injectability of these biologics," Jayaprakash says. "Regardless of how viscous your drug is, you can inject it, and this is what made this approach very attractive to us."

Biologic drugs include protein-based formulations and are harvested from living cells. They are used to treat a wide range of diseases and disorders, and can bind with specific tissues or immune cells as desired, provoking fewer unwanted reactions and bringing about particular immune responses that don't occur with other drugs.

"You can tailor very specific proteins or molecules that bind to very specific receptors in the body," says Jayaprakash. "They enable a degree of personalization, specificity, and immune response that just isn't available with small-molecule drugs. That's why, globally, people are pushing toward biologic drugs."